Research and Markets: Pricing patterns for Monoclonal Antibodies (mAbs) are ... Business Wire (press release) There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient's lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues ... |
